{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:18:20Z","timestamp":1788985100762,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01858-z","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:11:48Z","timestamp":1784002308000},"page":"4273-4292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials"],"prefix":"10.1007","volume":"16","author":[{"given":"Melinda J.","family":"Gooderham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Miller-Monthrope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ringuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"3","key":"1858_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1858_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s12325-021-01630-z","volume":"38","author":"SG Kwatra","year":"2021","unstructured":"Kwatra SG, Gruben D, Fung S, DiBonaventura M. Psychosocial comorbidities and health status among adults with moderate-to-severe atopic dermatitis: a 2017 US national health and wellness survey analysis. Adv Ther. 2021;38(3):1627\u201337.","journal-title":"Adv Ther"},{"issue":"1","key":"1858_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1858_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1858_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3109\/09546630903401470","volume":"21","author":"SL Chen","year":"2010","unstructured":"Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144\u201356.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1858_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494\u2013503.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1858_CR7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1858_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1858_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaad.2025.05.1385","volume":"93","author":"LF Eichenfield","year":"2025","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: results from TRuE-AD3, a phase 3, randomized double-blind study. J Am Acad Dermatol. 2025;93(3):689\u201398.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1858_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1858_CR11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","volume":"160","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 2024;160(11):1161\u201370.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1858_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/pde.15840","volume":"42","author":"LF Eichenfield","year":"2025","unstructured":"Eichenfield LF, Serrao R, Prajapati VH, et al. Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients aged 2\u20135 years with mild-to-moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial. Pediatr Dermatol. 2025;42(2):296\u2013304.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"1858_CR13","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","volume":"177","author":"R Chopra","year":"2017","unstructured":"Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316\u201321.","journal-title":"Br J Dermatol"},{"issue":"1_suppl","key":"1858_CR14","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/1203475418803628","volume":"22","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22(1_suppl):10S-S16.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"1858_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.clindermatol.2018.05.011","volume":"36","author":"PP Vakharia","year":"2018","unstructured":"Vakharia PP, Cella D, Silverberg JI. Patient-reported outcomes and quality of life measures in atopic dermatitis. Clin Dermatol. 2018;36(5):616\u201330.","journal-title":"Clin Dermatol"},{"issue":"8","key":"1858_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"1858_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"2","key":"1858_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1858_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/09546634.2019.1612836","volume":"31","author":"MJ Cork","year":"2020","unstructured":"Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2020;31(6):606\u201314.","journal-title":"J Dermatolog Treat"},{"issue":"24","key":"1858_CR20","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"12","key":"1858_CR21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Thaci D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391.","journal-title":"N Engl J Med"},{"issue":"1","key":"1858_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12325-024-02974-y","volume":"42","author":"E Simpson","year":"2025","unstructured":"Simpson E, Fernandez-Penas P, de Bruin-Weller M, et al. Improvement across dimensions of disease with lebrikizumab use in atopic dermatitis: two phase 3, randomized, double-blind, placebo-controlled monotherapy trials (ADvocate1 and ADvocate2). Adv Ther. 2025;42(1):132\u201343.","journal-title":"Adv Ther"},{"issue":"10451","key":"1858_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Reich A, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024;404(10451):445\u201360.","journal-title":"Lancet"},{"issue":"6","key":"1858_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","volume":"24","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Pink AE, Blauvelt A, et al. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials. Am J Clin Dermatol. 2023;24(6):939\u201352.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1858_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1858_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(6):1560\u201372.","journal-title":"Allergy"},{"issue":"10290","key":"1858_CR27","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"issue":"12","key":"1858_CR28","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1080\/03007995.2018.1498329","volume":"34","author":"AA Hebert","year":"2018","unstructured":"Hebert AA, Stingl G, Ho LK, et al. Patient impact and economic burden of mild-to-moderate atopic dermatitis. Curr Med Res Opin. 2018;34(12):2177\u201385.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1858_CR29","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jdv.13689","volume":"30","author":"JG Holm","year":"2016","unstructured":"Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1858_CR30","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s13555-025-01503-1","volume":"15","author":"MJ Gooderham","year":"2025","unstructured":"Gooderham MJ, Hong HC, Wang D, et al. Network meta-analysis of 1.5% ruxolitinib cream versus systemic agents in the treatment of moderate atopic dermatitis. Dermatol Ther. 2025;15(11):3313\u201328.","journal-title":"Dermatol Ther"},{"key":"1858_CR31","doi-asserted-by":"crossref","unstructured":"Carrascosa JM, Prajapati VH, Hong CH, et al. (2025) Efficacy and safety of ruxolitinib cream in adults with moderate atopic dermatitis: results from TRuE-AD4, a phase 3b, randomized, double-blind, vehicle-controlled study. 15th Georg RAJKA International Symposium on Atopic Dermatitis; October 24\u201326; Melbourne, Australia.","DOI":"10.1016\/j.jid.2025.09.317"},{"issue":"1","key":"1858_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000321711","volume":"222","author":"C Bangert","year":"2011","unstructured":"Bangert C, Strober BE, Cork M, et al. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial. Dermatology. 2011;222(1):36\u201348.","journal-title":"Dermatology"},{"issue":"4","key":"1858_CR33","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","volume":"166","author":"R Bissonnette","year":"2012","unstructured":"Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012;166(4):853\u201360.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1858_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100251","volume":"4","author":"P Changelian","year":"2024","unstructured":"Changelian P, Xu C, Mnich S, et al. ATI-1777, a topical JAK1\/3 inhibitor, may benefit atopic dermatitis without systemic drug exposure: results from preclinical development and phase 2a randomized control study ATI-1777-AD-201. JID Innov. 2024;4(2):100251.","journal-title":"JID Innov"},{"issue":"1","key":"1858_CR35","doi-asserted-by":"publisher","first-page":"2480744","DOI":"10.1080\/09546634.2025.2480744","volume":"36","author":"ZC Chiesa Fuxench","year":"2025","unstructured":"Chiesa Fuxench ZC, Lai Z, Kuo Y, Nawaz H, Cotliar J. Ruxolitinib cream monotherapy for facial and\/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial. J Dermatolog Treat. 2025;36(1):2480744.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1858_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40257-023-00780-w","volume":"24","author":"LF Eichenfield","year":"2023","unstructured":"Eichenfield LF, Gower RG, Xu J, et al. Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged \u2265 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am J Clin Dermatol. 2023;24(4):623\u201335.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1858_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jamadermatol.2023.4990","volume":"160","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Tarabar S, Forman S, et al. Efficacy and safety of PF-07038124 in patients with atopic dermatitis and plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 2024;160(2):156\u201363.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1858_CR38","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/ics.12948","volume":"46","author":"N Frossard","year":"2024","unstructured":"Frossard N, Co\u00efc A, Saguet T, et al. Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class neutraligand targeting the chemokine TARC\/CCL17 in mild-to-moderate atopic dermatitis. Int J Cosmet Sci. 2024;46(3):468\u201377.","journal-title":"Int J Cosmet Sci"},{"issue":"11","key":"1858_CR39","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/1346-8138.16120","volume":"48","author":"K Fujita","year":"2021","unstructured":"Fujita K, Yagi M, Moriwaki S, Yoshida M, Graham D. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2\u00a0years and older with mild-to-moderate atopic dermatitis. J Dermatol. 2021;48(11):1640\u201351.","journal-title":"J Dermatol"},{"issue":"2","key":"1858_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.36849\/JDD.7295","volume":"22","author":"M Gooderham","year":"2023","unstructured":"Gooderham M, Kircik L, Zirwas M, et al. The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof of concept study. J Drugs Dermatol. 2023;22(2):139\u201347.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"1858_CR41","first-page":"s21","volume":"22","author":"K Hawley","year":"2023","unstructured":"Hawley K, Lio P, Nguyen T, Qureshi A, Emesiani C, Meckfessel M. A novel 3-step over-the-counter eczema regimen improves eczema severity, itch, and life quality: randomized study. J Drugs Dermatol. 2023;22(10):s21\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"1858_CR42","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/1346-8138.17451","volume":"51","author":"A Igarashi","year":"2024","unstructured":"Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S. Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase 3 trials. J Dermatol. 2024;51(11):1404\u201313.","journal-title":"J Dermatol"},{"issue":"2","key":"1858_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1346-8138.17587","volume":"52","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Tsuji G, Murata R, Fukasawa S, Yamane S. A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis. J Dermatol. 2025;52(2):247\u201355.","journal-title":"J Dermatol"},{"issue":"2","key":"1858_CR44","first-page":"155","volume":"12","author":"F Iraji","year":"2022","unstructured":"Iraji F, Sharif Makhmalzadeh B, Abedini M, Aghaei A, Siahpoush A. Effect of herbal cream containing Fumaria officinalis and silymarin for treatment of eczema: a randomized double-blind controlled clinical trial. Avicenna J Phytomed. 2022;12(2):155\u201362.","journal-title":"Avicenna J Phytomed"},{"issue":"1","key":"1858_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000532054","volume":"240","author":"ME Jacobson","year":"2024","unstructured":"Jacobson ME, Myles IA, Paller AS, Eichenfield LF, Simpson EL. A randomized, double-blind, placebo-controlled, multicenter, 16-week trial to evaluate the efficacy and safety of FB-401 in children, adolescents, and adult subjects (ages 2 years and older) with mild-to-moderate atopic dermatitis. Dermatology (Basel). 2024;240(1):85\u201394.","journal-title":"Dermatology (Basel)"},{"issue":"21","key":"1858_CR46","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.3390\/jcm11216477","volume":"11","author":"K Kamiya","year":"2022","unstructured":"Kamiya K, Saeki H, Tokura Y, Yoshihara S, Sugai J, Ohtsuki M. Proactive versus rank-down topical corticosteroid therapy for maintenance of remission in pediatric atopic dermatitis: a randomized, open-label, active-controlled, parallel-group study (anticipate study). J Clin Med. 2022;11(21):6477.","journal-title":"J Clin Med"},{"issue":"6","key":"1858_CR47","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","volume":"82","author":"BS Kim","year":"2020","unstructured":"Kim BS, Sun K, Papp K, Venturanza M, Nasir A, Kuligowski ME. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82(6):1305\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1858_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaad.2023.02.064","volume":"89","author":"M Kim","year":"2023","unstructured":"Kim M, Del Duca E, Cheng J, et al. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin. J Am Acad Dermatol. 2023;89(2):283\u201392.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1858_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2340\/00015555-0748","volume":"90","author":"RS Kirsner","year":"2010","unstructured":"Kirsner RS, Heffernan MP, Antaya R. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Derm Venereol. 2010;90(1):58\u201364.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1858_CR50","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bjd.21826","volume":"187","author":"MN Landis","year":"2022","unstructured":"Landis MN, Arya M, Smith S, et al. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol. 2022;187(6):878\u201387.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1858_CR51","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s13555-024-01254-5","volume":"14","author":"SY Lee","year":"2024","unstructured":"Lee SY, Park JS, Kim D, et al. Efficacy of a multi-lamellar emulsion containing a synthetic sphingosine kinase 1 activator and pseudoceramide in patients with atopic dermatitis: a randomized controlled trial. Dermatol Ther. 2024;14(9):2591\u2013605.","journal-title":"Dermatol Ther"},{"issue":"10","key":"1858_CR52","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.36849\/JDD.6729","volume":"21","author":"C Lynde","year":"2022","unstructured":"Lynde C, Poulin Y, Tan J, et al. Phase 2 trial of topical thykamine in adults with mild to moderate atopic dermatitis. J Drugs Dermatol. 2022;21(10):1091\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"1858_CR53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1346-8138.16792","volume":"50","author":"L Ma","year":"2023","unstructured":"Ma L, Zhang L, Kobayashi M, et al. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged \u22652\u2009years with mild-to-moderate atopic dermatitis. J Dermatol. 2023;50(7):847\u201355.","journal-title":"J Dermatol"},{"issue":"11","key":"1858_CR54","first-page":"390","volume":"30","author":"H Ma","year":"2024","unstructured":"Ma H, Zhao Y, Xia X. Efficacy of mometasone furoate cream sodium alginate skin repair mask in atopic dermatitis treatment. Altern Ther Health Med. 2024;30(11):390\u20138.","journal-title":"Altern Ther Health Med"},{"issue":"3","key":"1858_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/09546630903410158","volume":"21","author":"M Meurer","year":"2010","unstructured":"Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. J Dermatolog Treat. 2010;21(3):157\u201366.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1858_CR56","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjd.16014","volume":"178","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178(2):424\u201332.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1858_CR57","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021;85(4):854\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1858_CR58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1684\/ejd.2024.4738","volume":"34","author":"C Neubauer","year":"2024","unstructured":"Neubauer C, Kragl M, Braun T, et al. An oil-in-water emulsion containing a combination of ginger extract and synthetic cannabidiol with potent in vitro anti-inflammatory effects alleviates symptoms of atopic dermatitis in a clinical trial. Eur J Dermatol. 2024;34(4):416\u201324.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"1858_CR59","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2020.08.132","volume":"86","author":"T Niemeyer-van der Kolk","year":"2022","unstructured":"Niemeyer-van der Kolk T, Buters TP, Krouwels L, et al. Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. J Am Acad Dermatol. 2022;86(4):854\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"1858_CR60","doi-asserted-by":"publisher","first-page":"adv00170","DOI":"10.2340\/00015555-3489","volume":"100","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Tallman AM, Ports WC, Gerber RA, Tan H, Zielinski MA. Evaluating the efficacy of crisaborole using the atopic dermatitis severity index and percentage of affected body surface area. Acta Derm Venereol. 2020;100(13):adv00170.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1858_CR61","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","volume":"84","author":"AS Paller","year":"2021","unstructured":"Paller AS, Stein Gold L, Soung J, Tallman AM, Rubenstein DS, Gooderham M. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol. 2021;84(3):632\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1858_CR62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40257-024-00901-z","volume":"26","author":"EL Simpson","year":"2025","unstructured":"Simpson EL, Augustin M, Thaci D, et al. Ruxolitinib cream monotherapy improved symptoms and quality of life in adults and adolescents with mild-to-moderate atopic dermatitis: patient-reported outcomes from two phase III studies. Am J Clin Dermatol. 2025;26(1):121\u201337.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1858_CR63","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jaci.2021.09.024","volume":"149","author":"CW Park","year":"2022","unstructured":"Park CW, Kim BJ, Lee YW, et al. Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: phase 3, randomized, vehicle-controlled study (CAPTAIN-AD). J Allergy Clin Immunol. 2022;149(4):1340\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1858_CR64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","volume":"80","author":"J Peppers","year":"2019","unstructured":"Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89\u201398.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1858_CR65","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/ced\/llad098","volume":"48","author":"M Per\u00e4l\u00e4","year":"2023","unstructured":"Per\u00e4l\u00e4 M, Salava A, Malmberg P, Pelkonen AS, M\u00e4kel\u00e4 MJ, Remitz A. Topical tacrolimus versus corticosteroids in childhood moderate-to-severe atopic dermatitis and the impact on airway inflammation: a long-term randomized open-label study. Clin Exp Dermatol. 2023;48(6):660\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1858_CR66","first-page":"457","volume":"24","author":"MF Rahman","year":"2015","unstructured":"Rahman MF, Nandi AK, Kabir S, Kamal M, Basher MS, Banu LA. Topical tacrolimus versus hydrocortisone on atopic dermatitis in paediatric patients: a randomized controlled trial. Mymensingh Med J. 2015;24(3):457\u201363.","journal-title":"Mymensingh Med J"},{"issue":"6","key":"1858_CR67","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000536670","volume":"36","author":"A Rao","year":"2023","unstructured":"Rao A, Moussa AA, Erickson J, Briskey D. Efficacy of topical palmitoylethanolamide (Levagen+) for the management of eczema symptoms: a double-blind, comparator-controlled, randomized clinical trial. Skin Pharmacol Physiol. 2023;36(6):288\u201395.","journal-title":"Skin Pharmacol Physiol"},{"issue":"19","key":"1858_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/GZQW6681","volume":"27","author":"MJ Ridd","year":"2023","unstructured":"Ridd MJ, Wells S, MacNeill SJ, et al. Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT. Health Technol Assess. 2023;27(19):1\u2013120.","journal-title":"Health Technol Assess"},{"issue":"1","key":"1858_CR69","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjd.20655","volume":"186","author":"H Saeki","year":"2022","unstructured":"Saeki H, Baba N, Ito K, Yokota D, Tsubouchi H. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. Br J Dermatol. 2022;186(1):40\u20139.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1858_CR70","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s13555-022-00751-9","volume":"12","author":"H Saeki","year":"2022","unstructured":"Saeki H, Imamura T, Yokota D, Tsubouchi H. Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: a phase III, long-term, open-label study. Dermatol Ther. 2022;12(7):1589\u2013601.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1858_CR71","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s13555-024-01236-7","volume":"14","author":"H Saeki","year":"2024","unstructured":"Saeki H, Ohya Y, Baba N, Imamura T, Yokota D, Tsubouchi H. An interim report of a phase 3, long-term, open-label study to evaluate efficacy and safety of difamilast ointment in Japanese infants with atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(9):2443\u201355.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1858_CR72","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/ced.15024","volume":"47","author":"A Salava","year":"2022","unstructured":"Salava A, Per\u00e4l\u00e4 M, Pelkonen A, M\u00e4kel\u00e4 M, Remitz A. Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis: a 36-month follow-up study. Clin Exp Dermatol. 2022;47(5):889\u2013902.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1858_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.293","volume":"3","author":"L Samuelov","year":"2023","unstructured":"Samuelov L, Shemer A, Greenberger S, et al. SNG100, a novel topical treatment for moderate atopic dermatitis, in patients aged 6 years or older: a randomised, double-blind, active-controlled trial. Skin Health Dis. 2023;3(6):e293.","journal-title":"Skin Health Dis"},{"issue":"4","key":"1858_CR74","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/pde.12867","volume":"33","author":"L Schneider","year":"2016","unstructured":"Schneider L, Hanifin J, Boguniewicz M, et al. Study of the Atopic March: development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388\u201398.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"1858_CR75","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1542\/peds.2014-1990","volume":"135","author":"B Sigurgeirsson","year":"2015","unstructured":"Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597\u2013606.","journal-title":"Pediatrics"},{"key":"1858_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102002","volume":"60","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Lio PA, Simpson EL, et al. Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial. EClinicalMedicine. 2023;60:102002.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1858_CR77","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13555-024-01318-6","volume":"15","author":"EL Simpson","year":"2025","unstructured":"Simpson EL, Hebert AA, Browning J, et al. Tapinarof improved outcomes and sleep for patients and families in two phase 3 atopic dermatitis trials in adults and children. Dermatol Ther. 2025;15(1):111\u201324.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1858_CR78","first-page":"361","volume":"42","author":"P Somjorn","year":"2024","unstructured":"Somjorn P, Kamanamool N, Kanokrungsee S, Rojhirunsakool S, Udompataikul M. A cream containing linoleic acid, 5% dexpanthenol and ceramide in the treatment of atopic dermatitis. Asian Pac J Allergy Immunol. 2024;42(4):361\u20137.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"7","key":"1858_CR79","first-page":"35","volume":"16","author":"M Sowlati","year":"2023","unstructured":"Sowlati M, Orzan OA, Morariu SH, Etropolska Z, Veraldi S, Dimitrov S. Topical application of a formulation containing pea proteins and xyloglucan in adult patients with atopic dermatitis: a double-blind, parallel, randomized, placebo-controlled, multicenter study. J Clin Aesthet Dermatol. 2023;16(7):35\u201341.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"7","key":"1858_CR80","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/jdv.19807","volume":"38","author":"RJ Wolf","year":"2024","unstructured":"Wolf RJ, Chen A, Wieser J, et al. Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(7):1364\u201372.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1858_CR81","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40272-025-00682-w","volume":"27","author":"H Yang","year":"2025","unstructured":"Yang H, Li P, Shu H, et al. Efficacy and safety of proactive therapy with 2% crisaborole ointment in children with mild-to-moderate atopic dermatitis: a randomized controlled study. Paediatr Drugs. 2025;27(3):367\u201376.","journal-title":"Paediatr Drugs"},{"issue":"9","key":"1858_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13475","volume":"29","author":"JR Zhu","year":"2023","unstructured":"Zhu JR, Wang J, Wang SS. A single-center, randomized, controlled study on the efficacy of niacinamide-containing body emollients combined with cleansing gel in the treatment of mild atopic dermatitis. Skin Res Technol. 2023;29(9):e13475.","journal-title":"Skin Res Technol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01858-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01858-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01858-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:03:18Z","timestamp":1788984198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01858-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1858"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01858-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Melinda J. Gooderham has served as a principal investigator for AbbVie, Acelyrin, Akros Pharma Inc., Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Aristea, Aslan, Attovia, Bausch Health, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Coherus Biosciences, Dermira, Eli Lilly, Galderma SA, GlaxoSmithKline, Incyte Corp., Inmagene, JAMP, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, MoonLake, Nektar Therapeutics, Nimbus, Novartis, Oruka, Pfizer, Q32 Bio, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, Tarsus, UCB, Ventyx, and Vyne; has been a consultant for AbbVie, Akros Pharma, Amgen, Apogee, Aslan, Bausch Health, Boehringer Ingelheim International GmbH, Eli Lilly, Janssen, Kyowa Kirin, Novartis Pharmaceuticals, Sanofi Genzyme, Sun Pharma, and UCB; has been an advisory board member for AbbVie, Amgen, Apogee, Bausch Health, Boehringer Ingelheim International GmbH, Eli Lilly, Galderma SA, Incyte Corp., Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Union; and has been a paid speaker for AbbVie, Amgen, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim International GmbH, Eli Lilly, Galderma SA, Janssen, JAMP, LEO Pharma, L'Or\u00e9al, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB. H. Chih-ho Hong has served as a speaker, advisor, consultant, and\/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Galderma, GlaxoSmithKline, Incyte Corp., JAMP Pharma, Janssen, Kenvue, LEO Pharma, Medimmune, Merck, Mirimar, Organon, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, and UCB. Charles Lynde has served as a speaker and\/or consultant for AbbVie, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Eli Lilly, Fresnius Kabi, Galderma, GlaxoSmithKline, Incyte Corp., Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L'Or\u00e9al, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, Sun Pharma, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health and has served as a principal investigator for AbbVie, Acelyrin, Akros, Altius, Amgen, Aralez, Arcutis, Avillion, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, Concert, Dermavant, Devonian, Eli Lilly, Evelo, Galderma, GlaxoSmithKline, Incyte Corp., Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L'Or\u00e9al, Medexus, MedX, Merck, MoonLake, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, Sun Pharma, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health. Yvette Miller-Monthrope has served as an advisor, consultant, and\/or speaker for AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Fresenius Kabi, Galderma, Incyte Corp., Janssen, Sanofi, Sun Pharma, Novartis, and UCB. Vimal H. Prajapati has served as an advisor, consultant, and\/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, Concert, CorEvitas, Eczema Society of Canada, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte Corp., JAMP Pharma, Janssen, Johnson & Johnson, Kenvue, Knight Therapeutics, Kymera, LEO Pharma, Medexus, Novartis, Organon, Paladin, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant; served as an investigator for AbbVie, AnaptysBio, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte Corp., Janssen, Johnson & Johnson, LEO Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, Q32 Bio, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; and received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Julien Ringuet has served as an advisor, consultant, and\/or speaker for AbbVie, Amgen, Apogee, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Incyte Corp., Janssen, LEO Pharma, L\u2019Or\u00e9al, NKS Health, Novartis, Organon, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB and served as an investigator for AbbVie, Alumis, Amgen, Apogee, Aristea, ASLAN Therapeutics, Bristol Myers Squibb, Celgene, Concert Pharmaceuticals, Correvitas, DiCE Therapeutics, Incyte Corp., Innovaderm, Janssen, Kyowa Kirin, LEO Pharma, Merck, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. Irina Turchin has served as a speaker, advisor, consultant, or investigator for AbbVie, Amgen, Arcutis, Aristea, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Horizon Therapeutics, Incyte Corp., Janssen, Kiniksa, LEO Pharma, Mallinckrodt, MoonLake Immunotherapeutics, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and Ventyx Biosciences. Jensen Yeung is an Editorial Board member of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions; and has served as a consultant, investigator, or speaker or received honoraria from AbbVie, Amgen, Acrutis, Apogee, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Galderma, Incyte Corp., JAMP Pharma, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, and UCB. Kim A. Papp has received honoraria and\/or grants as a consultant, speaker, investigator, or scientific officer from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Eli Lilly and Company, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corp., Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB Pharma, and Zai Lab.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}